Metastatic prostate cancer patients treated with androgen deprivation therapy expressed a significantly higher TSP1 immunoreactivity in prostatic adenocarcinoma when compared to other metastatic prostate cancer patients who did not receive hormonal therapy [48]. This evidence concerns the gene THBS1 and metastatic prostate carcinoma.